Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study

<b><i>Introduction:</i></b> Achieving optimal glycemic control in patients with type 1 diabetes mellitus (PwT1DM) is essential to prevent complications. Continuous subcutaneous insulin infusion (CSII) systems combined with continuous glucose monitoring (CGM) have improved outcomes, but the effectiveness of additional technologies, such as mobile apps and hybrid closed-loop systems (HCLSs), remains unclear. This study evaluates glycemic control and quality of life (QoL) in adult PwT1DM transitioning from multiple daily injections (MDI) to a CSII, first with the Mylife™ Dose app and subsequently switching to an HCLS. <b><i>Materials and Methods:</i></b> This was a 10-month, multicenter, open-label sequential study involving 135 adults with type 1 diabetes (T1D), all of whom were using isCGM and MDI before transitioning to CSII, first with the Mylife Dose app and later to an HCLS. Glycemic control (glycated hemoglobin [HbA1c], time in range [TIR], time below range, time above range), insulin requirements, and QoL/treatment satisfaction/hypoglycemia perception (Diabetes Quality of Life questionnaire, Diabetes Treatment Satisfaction Questionnaire, Clarke's test) were measured at each of the four study visits. <b><i>Results:</i></b> Transitioning from MDI to CSII showed modest improvements in HbA1c (7.57%-7.42%; <i>P</i> = 0.02) and TIR (56.3%-60.4%; <i>P</i> < 0.01). The introduction of the Mylife Dose app did not provide significant additional improvements in glycemic control or QoL, although it provided an additional tool for diabetes management. However, switching to an HCLS resulted in substantial improvements in HbA1c (6.7%), TIR (73.1%), and QoL, with over 70% of patients achieving an HbA1c <7%. Insulin requirements increased slightly with the HCLS, primarily due to basal insulin. Adherence was high, with 88.1% completing the study. <b><i>Conclusions:</i></b> The Mylife Dose app does not improve glycemic control or QoL significantly but offers convenience for patients with T1D. In contrast, HCLSs provide significant metabolic and QoL benefits, supporting their integration into T1D management with appropriate reimbursement policies.

Authors

Institutions

Publication Details

Journal
Diabetes Technology & Therapeutics
Published
2025-09-30
DOI
https://doi.org/10.1177/15209156251363452
Citations
1
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
1.29
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study

Marta Hernández, Cristina Contreras, José F. Palomar, Edelmiro Menéndez Torre et al.
1 citations
Diabetes Technology & Therapeutics
Diabetes Management and Research
1.29
article

Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A Descriptive Open-Label Sequential Study

Marta Hernández, Cristina Contreras, José F. Palomar, Edelmiro Menéndez Torre, Manuela Moreira Rodríguez, Ana Megía, Ángel Rebollo Román, Elsa Fernández, María Laínez López, Andrea Ortiz Maldonado, Susana García-Cerro, Marta Ferrer‐García, Carmen Lambert, Francisco Javier Gómez Alfonso, Luisa Avino, Paula Andújar, Elías Delgado, Juan Girbés Borrás, Pedro Pujante, Rosa Corcoy, Cristina Serrano, Alberto B. Díez, Pablo Abellán Galiana, Begoña Pla Peris, Georgios Kyriakos, Laura Cotovad Bellas, Javier González López, M. López Díez, Clara Isabel Navarro Hoyas, Teresa Martínez Raimond, Berta Soldevilla Madorell, Olga Simó Servant, Amaya Veladesojo, Lidia Urbon, Nuria Bau Serrallonga
article en
1 citations

Abstract

<b><i>Introduction:</i></b> Achieving optimal glycemic control in patients with type 1 diabetes mellitus (PwT1DM) is essential to prevent complications. Continuous subcutaneous insulin infusion (CSII) systems combined with continuous glucose monitoring (CGM) have improved outcomes, but the effectiveness of additional technologies, such as mobile apps and hybrid closed-loop systems (HCLSs), remains unclear. This study evaluates glycemic control and quality of life (QoL) in adult PwT1DM transitioning from multiple daily injections (MDI) to a CSII, first with the Mylife™ Dose app and subsequently switching to an HCLS. <b><i>Materials and Methods:</i></b> This was a 10-month, multicenter, open-label sequential study involving 135 adults with type 1 diabetes (T1D), all of whom were using isCGM and MDI before transitioning to CSII, first with the Mylife Dose app and later to an HCLS. Glycemic control (glycated hemoglobin [HbA1c], time in range [TIR], time below range, time above range), insulin requirements, and QoL/treatment satisfaction/hypoglycemia perception (Diabetes Quality of Life questionnaire, Diabetes Treatment Satisfaction Questionnaire, Clarke's test) were measured at each of the four study visits. <b><i>Results:</i></b> Transitioning from MDI to CSII showed modest improvements in HbA1c (7.57%-7.42%; <i>P</i> = 0.02) and TIR (56.3%-60.4%; <i>P</i> < 0.01). The introduction of the Mylife Dose app did not provide significant additional improvements in glycemic control or QoL, although it provided an additional tool for diabetes management. However, switching to an HCLS resulted in substantial improvements in HbA1c (6.7%), TIR (73.1%), and QoL, with over 70% of patients achieving an HbA1c <7%. Insulin requirements increased slightly with the HCLS, primarily due to basal insulin. Adherence was high, with 88.1% completing the study. <b><i>Conclusions:</i></b> The Mylife Dose app does not improve glycemic control or QoL significantly but offers convenience for patients with T1D. In contrast, HCLSs provide significant metabolic and QoL benefits, supporting their integration into T1D management with appropriate reimbursement policies.

Diabetes Technology & TherapeuticsVol. 27(10)
Hospital de Sant Pau (ES), Hospital Universitari Arnau de Vilanova (ES), Hospital Virgen de la Luz (ES), Complejo Hospitalario Universitario de Santiago (ES), Hospital Sierrallana (ES), Hospital Universitario Miguel Servet (ES), Hospital Rio Carrion (ES), Hospital Arnau de Vilanova (ES), Hospital El Bierzo (ES), Hospital Universitario Reina Sofía (ES), Hospital General Universitari de Castelló (ES), Hospital San Juan de Dios (CL), Vall d'Hebron Hospital Universitari (ES), Hospital Juan Ramón Jiménez (ES), Hospital de Cruces (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Complexo Hospitalario Universitario A Coruña (ES), Santa Lucía University General Hospital (ES), Hospital General de Elda (ES), Hospital Universitari Joan XXIII de Tarragona (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Universitari de Girona Doctor Josep Trueta (ES), Instituto de Investigación Sanitaria del Principado de Asturias (ES)
Openalex Percentile: Top 17%
Diabetes Management and Research
1.29
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.